Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that international rating agency S&P Global Ratings upgraded the company’s long-term credit rating from BB+ to BBB-, with a stable outlook. The upgrade follows recent rating increases by Moody's and Fitch, completing the company’s return to full investment-grade status at all three major rating agencies.
The return to investment grade marks a significant financial milestone for the pharmaceutical giant, following several years during which its debt traded at lower levels. The official announcement of the upgrade was issued from Tel Aviv on September 4, 2026, marking the completion of the broader financial process with all the rating agencies that cover the company’s debt.

What Factors Led to the Rating Upgrade?
S&P’s official report emphasized that the rating upgrade reflects a clear expectation of sustainable growth at Teva. The improvement in the company’s financial and business performance is based on several key factors, foremost among them particularly strong performance in innovative medicines, including the continued expansion and sales of the company’s flagship products worldwide.
In addition to growth in innovative medicines, S&P points to significant stabilization in generics, which constitute the company’s core generic business worldwide. Another key factor contributing to the positive assessment is Teva’s advanced drug pipeline, which includes key products (Pipeline) currently in advanced and promising stages of development.

Teva Chief Financial Officer Eli Kalif commented on the decision, saying: “The series of rating upgrades Teva has received within just a few months reflects the successful implementation of our ‘Pivot to Growth’ strategy and the significant progress we have made in reducing debt and strengthening our financial profile. This milestone gives us greater financial flexibility to continue investing in growth drivers and create long-term value for shareholders.”
How Does the Move Affect Teva’s Business Positioning?
The completion of the series of rating upgrades is an integral part of the comprehensive transformation Teva has undergone in recent years. The company is gradually shifting from a traditional generics company to an innovative biopharmaceutical company, while maintaining its global leadership in generics. This repositioning is intended to ensure the company’s continued growth in global markets.

Beyond the change in image and business positioning, the upgrade has direct and important financial implications for Teva’s activity in the capital markets. The return to full investment-grade status directly reduces the company’s financing costs and significantly increases its access to international capital markets, giving it greater financial flexibility to continue developing its business.










